Literature DB >> 23569986

Science behind cisplatin-induced nephrotoxicity in humans: a clinical study.

P A Arunkumar1, G L Viswanatha, N Radheshyam, H Mukund, M S Belliyappa.   

Abstract

OBJECTIVE: To investigate the relationship between serum electrolyte changes and cisplatin induced nephrotoxicity.
METHODS: We collected data from 18 patients undergoing cisplatin chemotherapy including serum electrolytes, creatinine, blood urea nitrogen (BUN) and urine potassium, sodium and pH levels before and after the cisplatin chemotherapy. All the patients had cancer and were treated with 40-50 mg/day cisplatin. Renal injury was assessed by measuring serum electrolytes, creatinine, BUN levels and urine potassium, sodium and pH levels.
RESULTS: The five cycles of cisplatin based chemotherapy resulted in hypomagnesia (P=0.029), hypocalcaemia (P=0.001*), hypophosphatemia (P=0.003*), hypokalemia (P=0.001*) and increased serum creatinine (P=0.001*) and BUN (P=0.292*) levels. In urine analysis, decrease in potassium (P=0.024*) was found, except potassium there was no significant changes in sodium and urine pH.
CONCLUSIONS: The present study demonstrates that, acute nephrotoxicity was observed in patients with different types of cancers undergoing cisplatin based chemotherapy due to electrolyte disturbances, when no corrective measures were initiated.

Entities:  

Keywords:  Cisplatin; Creatinine; Electrolyte imbalance; Hypocalcaemia; Hypomagnesia

Mesh:

Substances:

Year:  2012        PMID: 23569986      PMCID: PMC3609353          DOI: 10.1016/S2221-1691(12)60112-9

Source DB:  PubMed          Journal:  Asian Pac J Trop Biomed        ISSN: 2221-1691


  4 in total

Review 1.  Cisplatin-induced renal salt wasting syndrome.

Authors:  Tamim Hamdi; Shadi Latta; Bassel Jallad; Fayez Kheir; Mohamad N Alhosaini; Ashok Patel
Journal:  South Med J       Date:  2010-08       Impact factor: 0.954

2.  Serum potassium, calcium and magnesium in patients receiving ESHAP chemotherapy for relapsed lymphomas.

Authors:  J Zekri; N L Cheah; L Evans; B Hancock
Journal:  J R Coll Physicians Edinb       Date:  2009-12

3.  Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study.

Authors:  A Surendiran; N Balamurugan; K Gunaseelan; Shahid Akhtar; K S Reddy; C Adithan
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

4.  Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.

Authors:  Lubomir Bodnar; Gabriel Wcislo; Agnieszka Gasowska-Bodnar; Agnieszka Synowiec; Katarzyna Szarlej-Wcisło; Cezary Szczylik
Journal:  Eur J Cancer       Date:  2008-09-14       Impact factor: 9.162

  4 in total
  13 in total

1.  Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.

Authors:  Melanie S Joy; Lauren M Aleksunes; Blessy George; Xia Wen; Nickie Mercke; Madeleine Gomez; Cindy O'Bryant; Daniel W Bowles; Yichun Hu; Susan L Hogan
Journal:  Clin Pharmacol Ther       Date:  2017-02-14       Impact factor: 6.875

2.  CD4 T cell knockout does not protect against kidney injury and worsens cancer.

Authors:  Kameswaran Ravichandran; Qian Wang; Abdullah Ozkok; Alkesh Jani; Howard Li; Zhibin He; Danica Ljubanovic; Mary C Weiser-Evans; Raphael A Nemenoff; Charles L Edelstein
Journal:  J Mol Med (Berl)       Date:  2015-12-01       Impact factor: 4.599

3.  The nephroprotective effects of allicin and ascorbic acid against cisplatin-induced toxicity in rats.

Authors:  Mohamed M Abdel-Daim; Abdelrahman Ibrahim Abushouk; Thoria Donia; Saud Alarifi; Saad Alkahtani; Lotfi Aleya; Simona G Bungau
Journal:  Environ Sci Pollut Res Int       Date:  2019-03-25       Impact factor: 4.223

4.  Improved Chemotherapy Outcomes of Patients With Small-cell Lung Cancer Treated With Combined Alkalization Therapy and Intravenous Vitamin C.

Authors:  Reo Hamaguchi; Ryoko Narui; Hiromasa Morikawa; Hiromi Wada
Journal:  Cancer Diagn Progn       Date:  2021-07-03

5.  Danshen modulates Nrf2-mediated signaling pathway in cisplatin-induced renal injury.

Authors:  Si-Si Cao; Miao Yan; Zhen-Yan Hou; Ying Chen; Yun-Sheng Jiang; Xin-Rong Fan; Ping-Fei Fang; Bi-Kui Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

6.  Anthocyanin - Rich Red Dye of Hibiscus Sabdariffa Calyx Modulates Cisplatin-induced Nephrotoxicity and Oxidative Stress in Rats.

Authors:  Adedayo O Ademiluyi; Ganiyu Oboh; Oluwaseun J Agbebi; Ayodele J Akinyemi
Journal:  Int J Biomed Sci       Date:  2013-12

7.  Phytochemical evaluation of roots of Plumbago zeylanica L. and assessment of its potential as a nephroprotective agent.

Authors:  R Rajakrishnan; R Lekshmi; P B Benil; J Thomas; A H AlFarhan; V Rakesh; S Khalaf
Journal:  Saudi J Biol Sci       Date:  2017-01-08       Impact factor: 4.219

8.  Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer.

Authors:  Ivette J Suárez-Arroyo; Yaliz Loperena-Alvarez; Raysa Rosario-Acevedo; Michelle M Martínez-Montemayor
Journal:  Medicines (Basel)       Date:  2017-03-15

9.  Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin's lymphoma: a case report.

Authors:  Shereen Elazzazy; Hager A El-Geed; Sumaya Al Yafei
Journal:  Int Med Case Rep J       Date:  2013-01-04

10.  Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.

Authors:  Marília Berlofa Visacri; Eder de Carvalho Pincinato; Graziele Baldan Ferrari; Júlia Coelho França Quintanilha; Priscila Gava Mazzola; Carmen Silvia Passos Lima; Patricia Moriel
Journal:  Daru       Date:  2017-04-24       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.